European Pharmaceutical Review

NOVEMBER 1, 2023

WHO referred to 61 bacterial vaccine candidates in diverse stages of clinical development. WHO referred to 61 bacterial vaccine candidates in diverse stages of clinical development Prior to COVID-19, Streptococcus pneumoniae (also known as the pneumococcus) represented the biggest vaccine market in the world.

Vaccines 104

Vaccines Immunization 104

Pharmaceutical Technology

JANUARY 22, 2024

Pneumococcal (23-valent) vaccine is under clinical development by Jiangsu Ab&b Bio-tech and currently in Phase I for Streptococcal Pneumonia.

Vaccines 40

Vaccines 40

Pharmaceutical Technology

JANUARY 22, 2024

Pneumococcal (23-valent) vaccine is under clinical development by Jiangsu Ab&b Bio-tech and currently in Phase I for Streptococcal Pneumonia.

Vaccines 40

Vaccines 40

Pharmaceutical Technology

JUNE 23, 2022

The US Food and Drug Administration (FDA) has granted approval for Merck's (MSD outside the US and Canada) pneumococcal 15-valent conjugate vaccine, Vaxneuvance, for use in children aged six weeks to 17 years. The post US FDA grants approval for Merck’s pneumococcal vaccine for children appeared first on Pharmaceutical Technology.

Vaccines 59

Vaccines FDA Research Laboratories Immunization 59

European Pharmaceutical Review

SEPTEMBER 26, 2022

Positive top-line Phase III study results from Pfizer’s major 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) indicate that it could help prevent invasive pneumococcal disease (IPD) and pneumonia. The seven serotypes included in 20vPnC vaccine cause most cases of invasive pneumococcal disease (IPD) worldwide.

Vaccines 80

Vaccines 80

Pharmaceutical Technology

OCTOBER 28, 2022

On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. This is in addition to its long-available pneumococcal polysaccharide vaccine PPSV23.

Vaccines 64

Vaccines FDA Immunization 64

pharmaphorum

JULY 19, 2021

The FDA has approved a new pneumococcal vaccine from Merck & Co, just over a month after Pfizer got a green light for a new version of its market leading Prevnar shot. Merck’s Vaxneuvance – formerly known as V114 – is the first major competition to Pfizer’s franchise in the big market for conjugate pneumococcal vaccines.

FDA 52

FDA Vaccines Immunization 52

pharmaphorum

JUNE 9, 2021

Pfizer has the FDA approval it was seeking for Prevnar 20, the latest update to its blockbuster pneumococcal vaccination franchise, keeping it one step ahead of a competing shot from Merck & Co. Around 10,000 American adults a year die as a result of IPD.

FDA 52

FDA Vaccines Immunization 52

pharmaphorum

SEPTEMBER 30, 2021

Pfizer’s new Prevnar 20 conjugate pneumococcal vaccine can be dosed at the same time as the seasonal flu jab, without any impact on either shot’s effectiveness, according to a new study. “However, vaccination rates decline when someone needs to make multiple appointments to receive these vaccines,” he added. .

Vaccines 52

Vaccines Immunization 52

pharmaphorum

MARCH 23, 2022

Merck & Co’s chief medical officer and head of clinical development Dr Roy Baynes has announced his retirement from the company to take up a new role alongside his former colleague Roger Perlmutter at biotech Eikon Therapeutics. billion last year. billion last year.

Vaccines 98

Vaccines FDA 98

Pharmaceutical Technology

JULY 13, 2022

Furthermore, Orion will oversee the manufacturing of ODM-208 for clinical and commercial supply. In June this year, the US Food and Drug Administration approved Merck’s pneumococcal 15-valent conjugate vaccine, Vaxneuvance, for children aged six weeks to 17 years.

Research Laboratories 105

Research Laboratories Vaccines 105

pharmaphorum

DECEMBER 1, 2021

The vaccine has just started clinical testing, but is designed to control the growth of C acnes on the skin and prevent it from damaging the cellular lining of pores, which can lead to scarring in severe acne cases. It will highlight vaccines for pneumococcal disease, meningitis, respiratory syncytial virus (RSV), influenza, and chlamydia.

Vaccines 105

Vaccines FDA 105

pharmaphorum

JANUARY 31, 2022

Today, Pfizer said it was discontinuing the programme, saying the magnitude of response seen in the trial “did not support continuation of…clinical development” in cardiovascular (CV) risk reduction and severe hypertriglyceridaemia (SHTG). billion at the back end in milestone payments, but will now return rights to Ionis.

Vaccines 52

Vaccines FDA Hospitals 52

ISPE

SEPTEMBER 13, 2023

billion doses annually), which includes polio, diphtheria, tetanus, pertussis, Hib, BCG, r-hepatitis B, measles, mumps, rubella, and pneumococcal vaccines. SERUM is ranked as India’s number one biotechnology company and the world’s largest vaccine manufacturer by the number of doses produced and sold globally (more than 2.5

Vaccines 98

Vaccines 98

PQA

AUGUST 8, 2022

Between 2019 and 2021, PQS has significantly contributed to the industry’s further understanding of how to utilize pharmacy as a clinical practice by helping to bring awareness of the impact pharmacy staff can have on their communities. Medicare Advantage–pharmacy partnership improves influenza and pneumococcal vaccination rates.

Independent Pharmacies 52

Independent Pharmacies Community Pharmacies Patient Care Vaccines 52

pharmaphorum

JANUARY 31, 2022

According to Saad, this includes “data from different domains: real-world data, clinical data, post-market data, all those different data sets”. Shanaya Deboo is vice president, marketing, at Pfizer, where she leads the Global Adult Pneumococcal Vaccine Franchise.

Vaccines 97

Vaccines Pharmaceutical Companies Pharmaceutical Companies Communication 97

The Checkup by Singlecare

OCTOBER 27, 2023

Key takeaways: Clinical studies have raised concern that antibiotics like amoxicillin-potassium clavulanate could reduce the effectiveness of estrogen-based contraceptives, namely birth control pills, increasing the chance of unintended pregnancy.

Adverse Reactions 52

Adverse Reactions Labelling Chemotherapy Communication 52

pharmaphorum

JULY 14, 2021

Already facing one rival to its blockbuster pneumococcal vaccine Prevnar, Pfizer could have another to contend with, after Affinivax reported positive phase 2 results with its ASP3772 candidate – plus a new breakthrough designation from the FDA.

Vaccines 52

Vaccines Immunization FDA 52

IDStewardship

DECEMBER 22, 2022

My favorite was SAFER which was a randomized placebo controlled trial out of Canadian emergency rooms of children with chest X-ray findings consistent with pneumonia showing five days amoxicillin + five days placebo was as effective as 10 days amoxicillin for clinical cure at two to three weeks. pneumoniae. Group A Streptococcal Pharyngitis.

238

238

pharmaphorum

OCTOBER 21, 2020

Merck & Co has built more momentum behind its attempt to depose Pfizer’s blockbuster pneumococcal conjugate vaccine Prevnar 13, with two new phase 3 trials backing its rival shot V114. It also provides an opportunity to expand its position in the adult pneumococcal disease market, where Pneumovax 23 is still widely used.

Vaccines 52

Vaccines Immunization 52